Boehringer and Sarah Cannon team for immune-oncology venture
BI, Boehringer Ingelheim, checkpoint inhibitors, immunooncology, Sarah Cannon Research Institute
0 Comment
Partnership will seek to develop two immune checkpoint inhibitor candidates.